Executive Chairman, Vertex Pharmaceuticals
Search every verified Jeffrey Leiden interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Jeffrey Leiden, Executive Chairman and former CEO of Vertex Pharmaceuticals, discussed the company's shift in drug development strategy on the Kinara podcast in May 2026. He described moving away from the traditional "shots on goal" approach, which he said is outdated, and instead focusing on validated targets known from human genetics or pharmacology to be the underlying cause of a disease. Leiden recounted the lengthy development process for the non-opioid pain medication Journavx, noting that a pivotal moment came in 2015 when he considered ending the program after years of effort, but was persuaded by a scientist to continue funding for two more years. Leiden has also been active in community philanthropy. At an April 2024 event hosted by Whittier Street Health Center, he was honored for his contributions and spoke about the center's programs, which include behavioral health and childhood obesity initiatives. During the COVID-19 pandemic in March 2020, Leiden stated that Vertex expected some impact on clinical trials, with possible temporary pauses in new patient enrollment, and described the company's participation in the Boston Resiliency Fund, which he said surpassed its $10 million goal within a day. Earlier in his career, he received the Henri A. Termeer Innovative Leadership Award from MassBio in 2018 and was inducted into the Academy of Distinguished Bostonians that same year.
Jeff Leiden, Executive Chairman and Former CEO of Vertex Pharmaceuticals, joins the Kinara podcast to discuss the change in approach that resulted in the innovative non-opioid pain medication Journavx. He also details how pharma's traditional "shots on goal" approach – more shots, more chances of developing a breakthrough drug – is outdated in the current commercialization climate.
On April 3rd, 2024, Whittier Street Health Center hosted a Toast celebration of the long and impactful legacy of Dr. Jeff Leiden, a High School Dropout, Physician, Scientist and Innovator. Dr. Leiden is the Executive Chairman of the board and past CEO and President of Vertex Pharmaceuticals, an innovative company with a deep commitment to investing in science, transforming lives and prioritizing corporate social responsibility. Funds raised from this event supports Whittier’s innovative, culturally sensitive and high quality health care and social programs and services for more than 30,000 p…
CNBC's Meg Tirrell interviews Vertex CEO Jeff Leiden on how coronavirus is impacting its supply chain and drug trials. For more coronavirus live updates: https://www.cnbc.com/2020/03/27/coron... For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://www.cnbc.com/pro/?__source=yo... » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates C…
Dr. Jeffrey Leiden was inducted into the Academy of Distinguished Bostonians during the Greater Boston Chamber of Commerce’s Annual Meeting on May 15, 2018. This prestigious group includes some of Boston’s most accomplished business leaders, philanthropists, local and national elected officials, cultural dignitaries, and sports greats.
Wednesday, March 21, 2018.
Jeffrey Leiden, MD, PhD, is the Chairman, President and Chief Executive Officer of Vertex Pharmaceuticals. Dr. Leiden has more than 20 years of scientific, commercial and financial experience in the pharmaceutical and biotechnology industries and clinical experience in academia as a practicing cardiologist and molecular biologist. Learn more at http://takingontomorrow.org
Sign in to search the full transcript archive, filter by topic, and access every quote from Jeffrey Leiden.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans